Cancer drug gets Needle-Shy: new injection method tested
NCT ID NCT07391670
Summary
This early-stage study is testing a new way to give the cancer drug durvalumab as an injection under the skin instead of through an IV. Researchers want to find a dose that works as well as the IV version and check if it's safe. The study will enroll 40 adults with certain advanced solid tumors, including lung and liver cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOURS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
Fitzroy, 3065, Australia
-
Research Site
St Albans, 3021, Australia
-
Research Site
Woolloongabba, 4102, Australia
-
Research Site
Batumi, 6010, Georgia
-
Research Site
Tbilisi, 0112, Georgia
-
Research Site
Tbilisi, 0114, Georgia
-
Research Site
Brzozów, 36-200, Poland
-
Research Site
Koszalin, 75-581, Poland
-
Research Site
Lublin, 20-090, Poland
-
Research Site
Olsztyn, 10-357, Poland
-
Research Site
Przemyśl, 37-700, Poland
-
Research Site
Seongnam-si, 13620, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Seoul, 5505, South Korea
-
Research Site
Tainan, 73657, Taiwan
-
Research Site
Taipei, 110, Taiwan
-
Research Site
Taipei, 112, Taiwan
-
Research Site
Taoyuan District, 333, Taiwan
Conditions
Explore the condition pages connected to this study.